摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,6-dimethyl-N-[4-(methylsulfanyl)phenyl]furo[2,3-d]pyrimidin-4-amine | 1392817-31-0

中文名称
——
中文别名
——
英文名称
2,6-dimethyl-N-[4-(methylsulfanyl)phenyl]furo[2,3-d]pyrimidin-4-amine
英文别名
2,6-Dimethyl-N-[4-(methylsulfanyl)phenyl]furo[2,3-d]pyrimidin-4-amine;2,6-dimethyl-N-(4-methylsulfanylphenyl)furo[2,3-d]pyrimidin-4-amine
2,6-dimethyl-N-[4-(methylsulfanyl)phenyl]furo[2,3-d]pyrimidin-4-amine化学式
CAS
1392817-31-0
化学式
C15H15N3OS
mdl
——
分子量
285.37
InChiKey
KDWQAZJGTLQQBJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    76.2
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
    申请人:Gangjee Aleem
    公开号:US09139590B2
    公开(公告)日:2015-09-22
    Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.
    本发明提供了具有抗微管蛋白活性的双环和三环嘧啶酪氨酸激酶抑制剂。本发明的组合物具有单一制剂中的强效血管内皮生长因子受体抑制活性和抗微管蛋白活性的双重活性。还描述了这些组合物的溶性盐。本发明还揭示了使用这些组合物及其盐治疗患有癌症、黄斑变性和关节炎的患者的方法。
  • BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT
    申请人:Duquesne University of The Holy Spirit
    公开号:EP2670244B1
    公开(公告)日:2018-04-11
  • Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating a Patient
    申请人:Duquesne University of the Holy Spirit
    公开号:US20160009731A1
    公开(公告)日:2016-01-14
    Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.
  • Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating A Patient
    申请人:Duquesne University of the Holy Spirit
    公开号:US20210032266A1
    公开(公告)日:2021-02-04
    Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed.
  • US9139590B2
    申请人:——
    公开号:US9139590B2
    公开(公告)日:2015-09-22
查看更多

同类化合物

呋喃并[2,3-d]嘧啶-4(1H)-酮 呋喃并[2,3-d]嘧啶-2(3H)-酮 呋喃并[2,3-d]嘧啶 6-苯基呋喃并[2,3-D]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4(3H)-酮 6-(4-甲氧基苯基)呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲氧基苯基)-5-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲基苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(4-氯苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(3-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 5-甲基呋喃并[2,3-d]嘧啶-4-胺 5-溴呋喃并[2,3-D]嘧啶-4-胺 5-氯甲基呋喃并[2,3-d]嘧啶-2,4-二胺 5,6-二甲基呋喃[2,3-d]嘧啶-4-胺 4-氯呋喃[2,3-D]嘧啶 4-氯-6-甲基-呋喃并[2,3-d]嘧啶 4-氨基呋喃并[2,3-D]嘧啶 4,6-二甲基呋喃并[2,3-d]嘧啶 4,6-二甲基呋喃并[2,3-D]嘧啶-2-胺 3-(2-脱氧-beta-D-赤式-呋喃戊糖基)-6-甲基呋喃并[2,3-d]嘧啶-2(3H)-酮 2-甲基硫代呋喃并[2,3-d]嘧啶-6-甲醇 2,4-二氯呋喃并[2,3-d]嘧啶 2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶 2-Methyl-4-diacetylamino-5,6-bis-(2-furyl)furo<2,3-d>pyrimidine 3-[1-methyl-6-(5-nitro-furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-propan-1-ol 1-Methyl-4-(1-methyl-2-methoxy-ethyl-amino)-6-(5-nitro-2-furyl)-1H-pyrazolo<3.4-d>pyrimidin 2-Ethyl-4-amino-5,6-bis-(2-furyl)furo<2,3-d>pyrimidine 3-[3’,5’-di-O-(tert-butyldimethylsilyl)-2’-deoxy-β-D-ribofuranosyl]-6-(p-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 2,6-dimethyl-3H-furo[2,3-d]pyrimidine-4-thione 4-hydrazino-6-methyl-2-phenyl-furo[2,3-d]pyrimidine 3-[3'-O-(tert-butyldimethylsilyl)-2'-deoxy-β-D-ribofuranosyl]-6-(p-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 4-Ethylamino-6-methylfuro<4,5-b>pyrimidin 6-[Diethoxy(oxido)phosphaniumyl]furo[2,3-d]pyrimidine t counted 4-methoxy-2,6-dimethyl-furo[2,3-d]pyrimidine 3-(2-deoxy-β-D-erythro-pentofuranosyl)-6-ethynyl-furo[2,3-d]pyrimidin-2(3H)-one ethyl (4-oxo-5-phenyl-3,4-dihydrofuro[2,3-d]pyrimidin-2-yl)acetate 2,2'-[3-methyl-6-(5-nitro-furan-2-yl)-isoxazolo[5,4-d]pyrimidin-4-ylazanediyl]-bis-ethanol 5-[(R/S)-2-(2'-methoxyphenyl)pentyl]furo[2,3-d]pyrimidine-2,4-diamine 5-acetyl-6-(benzyloxy)-2,4-dimethylfuro<2,3-b>pyridine 5-[(R/S)-2-(2'-methoxyphenyl)-3-methylbutyl]furo[2,3-d]-pyrimidine-2,4-diamine furan-2-carboxylic acid N'-{2-amino-7-[2-(t-butyldimethylsilanyloxy)ethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-hydrazide 2-(5-phenylfuro[2,3-d]pyrimidin-4-ylamino)ethanol 5-[(R/S)-2-(2'-methoxyphenyl)-4-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine 5-[(R/S)-2-(2'-methoxyphenyl)hexyl]furo[2,3-d]pyrimidine-2,4-diamine tert-butyl 3-<6'-(benzyloxy)-2',4'-dimethylfuro<2,3-b>-pyrid-5'-yl>-3-hydroxybutanoate 6-(benzyloxy)-2,4-dimethylfuro<2,3-b>pyridine-5-carboxaldehyde